ClinicalTrials.gg
RecruitingNCT07245992DekaJointUpdated Oct 14, 2026

A Study of F8IL10 Intra-articular Treatment in Rheumatoid Arthritis

A Phase 1 interventional study of F8IL10 in Rheumatoid Arthritis (RA), sponsored by Philogen S.p.A.. Recruiting at 2 sites in Italy. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Philogen S.p.A. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Oct 14, 2026Enrollment updatedPrimary outcomes revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
54
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 188 studies in Arthritis, Rheumatoid with a site in Italy — 19 open to participants now, 29 under way, 3 of them phase 3. Arthritis, Rheumatoid · Italy.

Planned enrollment
131st of 145
54 · median 323
Started
2026
with 4 others
Phase 1
8 of 188
4 open now
Primary completion
2028-09
later than 21 of 28 live
Registered
183rd of 188
by date

Among the 188 studies in Arthritis, Rheumatoid with a site in Italy, this one is the 131st largest by planned enrollment of the 145 interventional ones that give a count, is one of 5 that started in 2026, is one of 8 in phase 1, reaches primary completion later than 21 of the 28 other live ones, and was the 183rd registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

19 of the 188 studies in Arthritis, Rheumatoid with a site in Italy are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 188 studies in Arthritis, Rheumatoid with a site in Italy, or all of them as a file.
02

Study summary

The aim of this study is to evaluate the safety of F8IL10 when administered by intra-articular injection and to determine the maximum tolerated dose (MTD) in order to establish the recommended dose (RD) in patients with Reumatoid Arthritis.

Read the detailed description

This protocol describes an open-label, non-randomized, ascending-dose Phase I study conducted in sequential cohorts of patients. The aim of the study is to assess the safety and tolerability of F8IL10 when administered via intra-articular (IA) route 3 times every 4 weeks in patients with RA.

Eligible patients are male or female, ≥18 and ≤80 years old, with Rheumatoid Arthritis (RA) who, despite treatment with stable doses for at least 3 months of DMARDs (conventional, biologic and/or targeted synthetic), present arthritis flare(s) suitable for IA injection in a knee, shoulder, ankle, wrist or elbow.

The study will take place in two stages:

  1. The dose-escalation part is designed with an accelerated phase, followed by a classical 3+3 dose-escalation scheme. Patients will be sequentially assigned to the following F8IL10 concentration levels:

    • Cohort 1: 0.05 µg/mL
    • Cohort 2: 0.5 µg/mL
    • Cohort 3: 5 µg/mL
    • Cohort 4: 20 µg/mL
    • Cohort 5: 50 µg/mL
    • Cohort 6: 100 µg/mL
    • Cohort 7: 150 µg/mL
    • Cohort 8: 200 µg/mL The administered volume depends on the target joint: 5 mL for knee, 4 mL for shoulder, 2 mL for ankle or elbow, and 1 mL for wrist. Therefore, the actual administered dose varies according to both the cohort concentration and the joint treated.
  2. Following successful identification of the RD, the study will proceed with a dose-expansion part, during which 12 patients will be treated at the RD concentration level, including those already treated at that level during dose escalation.

Patients will receive intra-articular administrations of F8IL10 every 4 weeks for up to 3 administrations, at Week 1, Week 5 and Week 9. Following completion of treatment, patients will continue with Follow-up every 4 weeks from Week 13, or End of Treatment, up to Week 37, to monitor safety, treatment response and any need to introduce or modify DMARD therapy.

The primary objective is to evaluate the safety of F8IL10 when administered by IA injection and to determine the maximum tolerated dose (MTD) in order to establish the recommended dose (RD). MTD, RD and maximum administered dose (MAD) are defined as joint-independent F8IL10 concentrations applicable across all evaluated joint types.

Secondary objectives are to assess early signs of efficacy and to determine the pharmacokinetic profile and immunogenicity of intra-articular F8IL10

03

Conditions studied

  • Rheumatoid Arthritis (RA)

Keywords

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients aged ≥18 and ≤80 years.
  2. Diagnosis of RA according to ACR/EULAR classification criteria (2010) with a disease duration exceeding 6 months.
  3. Presence of arthritis flare(s) suitable for IA injection in a knee, ankle, shoulder, wrist or elbow, despite treatment with stable doses (for at least 3 months) of DMARDs (conventional, biologic, and targeted synthetic) background therapy.
  4. No or stable regimens of NSAIDs and/or oral (≤ 10 mg/day; prednisone equivalent) for a period ≥2 weeks prior to screening.
  5. All acute toxic effects of any prior therapy must have resolved or returned to classification "mild" (grade 1) according to v.5.0.
  6. Sufficient hematologic, liver and renal function defined as follows:

    • (ANC) ≥1.5 x 109/L, ≥100 x109/L, (Hb) ≥10.0 g/dL.
    • Alkaline Phosphatase (AP), (ALT) and or Aspartate Aminotransferase (AST) ≤3 x (ULN), and total ≤2.0 mg/dl (34.2 μmol/L).
    • Creatinine ≤1.5 ULN or 24 h ≥50 mL/min.
  7. Documented negative TB test (e.g. Quantiferon or equivalent).
  8. Documented negative test for --. For HBV serology, the determination of HBsAg and anti-HBcAg Ab is required. In patients with serology documenting previous exposure to HBV (i.e., anti-HBs Ab with no history of vaccination and/or anti-HBc Ab), negative serum HBV-DNA is required. For HCV, HCV-RNA or HCV antibody test is required. Subjects with a positive test for HCV antibody but no detection of HCV-RNA indicating no ongoing infection are eligible.
  9. Sexually active male or female patients of are eligible providing that:

    • Women of childbearing potential (WOCBP) have a negative pregnancy test performed within 4 weeks prior to treatment start.
    • WOCBP agree to use, from the screening to 6 months following the last study drug administration, effective method of as applicable per local law that both results in a Pearl index \<1 and considered highly effective as defined by the "Recommendations for contraception and pregnancy testing in clinical trials" issued by the "Clinical Trial Facilitation Group" (e.g. combined estrogen and progestogen containing hormonal contraception, progestogen-only hormonal contraception, intrauterine device, intrauterine hormone-releasing system, vasectomized partner, total sexual abstinence or bilateral tubal occlusion).
    • Males agree to use two acceptable methods of contraception (e.g. condom with spermicidal gel) from the screening to 6 months following the last study drug administration. Females of childbearing potential that are partners of male study participants must observe the same birth control indications that apply to female participants.
  10. Signed and dated Ethics Committee-approved form indicating that the patient, or patient's legally acceptable representative, has been informed of all pertinent aspects of the study.
  11. Willingness and ability to comply with the scheduled visits, treatment plan, laboratory tests and other study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Presence of additional RA flares or RA-related symptoms that, in the investigator's judgment, are likely to require local treatment during the study (defined as intra-articular or peri-articular injections/procedures intended to treat RA; e.g., joint, tendon-sheath, or bursal injections; hyaluronic acid; biologic/PRP injections; or radio synovectomy)._
  2. Presence of active infections or another severe concurrent disease, which, in the opinion of the investigator, would place the patient at undue risk or would interfere with the study objectives or conduct.
  3. Pregnancy, lactation or unwillingness to use adequate methods.
  4. Diagnosis of any other inflammatory arthritis or active diseases other than RA.
  5. Any therapy for RA apart from the allowed background therapy (i.e., stable doses of DMARDs, corticosteroids, and/or NSAIDs) within 4 weeks prior to the first IMP dosing.
  6. Received intra-articular administration of corticosteroids/DMARDs within 4 weeks or 5 half-lives prior to the first IMP dosing, whichever is longer.
  7. History or currently active primary or secondary immunodeficiency.
  8. Concurrent or history of malignancy (except in situ melanoma and low-risk non melanoma skin cancer) from which the patient has been disease-free for less than 2 years.
  9. History within the last year of acute or subacute coronary syndromes including myocardial infarction, unstable or severe stable angina pectoris.
  10. Treatment with warfarin or other coumarin derivatives.
  11. cardiac arrhythmias or requiring permanent medication.
  12. Abnormalities in baseline analysis that are considered as clinically significant by the investigator; subjects with current or a history of /QTc prolongation.
  13. Uncontrolled hypertension, despite optimal treatment.
  14. Known arterial aneurism at high risk of rupture.
  15. Ischemic peripheral vascular disease (Grade IIb-IV according to Leriche Fontaine classification).
  16. Severe diabetic retinopathy.
  17. Major trauma including surgery within 4 weeks prior to administration of study treatment.
  18. Known history of allergy/ or other intolerance to any component of F8IL10 (including ) or to other drugs based on human proteins/peptides/antibodies.
  19. Treatment with any agent within 4 weeks or 5 half-lives prior to the first dose of study drug, whichever is longer.
  20. Immunization with a live/attenuated vaccine within 4 weeks prior to baseline or plan to receive vaccines during the study.
  21. Non-RA related chronic pain disorders.
  22. Patients requiring stable doses of corticosteroids >10 mg/day (prednisone equivalent). Limited use of corticosteroids to treat or prevent acute hypersensitivity reactions is not considered an exclusion criterion.
  23. History of alcohol, drug or chemical substance abuse within the 6 months prior to screening.
  24. Any condition that in the opinion of the investigator could hamper compliance with the study protocol.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
54 participants (estimated)

Study arms

  • Experimental
    Treatment

    The study will take place in two stages: 1. In the dose-escalation part, participants will be enrolled in cohorts and treated at different F8IL10 concentration levels in order to identify a joint-independent recommended dose (RD), expressed as an F8IL10 concentration. In each cohort, 1 to 6 patients will be treated until the maximum administered dose (MAD) is reached. 2. Following successful identification of the RD, the study will proceed with a dose-expansion part, during which 12 patients will be treated at the RD concentration level, including those treated at that concentration during the dose-escalation part.

    Drug: F8IL10

Interventions

  • DrugF8IL10

    Intra-articular treatment

06

What researchers measure

Primary outcomes

  1. DLT

    Occurrence of dose limiting toxicity (DLT)

    Time frame: From Day 1 to Day 28 of the treatment

  2. MAD, MTD and RD

    Definition of maximum administered dose (MAD), maximum tolerated dose (MTD) and recommended dose (RD), each expressed as joint-independent F8IL10 concentrations applicable across all evaluated joint types.

    Time frame: From Day 1 to Day 28 of the treatment

  3. AEs, SAEs and DILI

    Adverse events (AEs), serious adverse events (SAEs) and Drug-Induced Liver Injury (DILI), based on Common Terminology Criteria for Adverse Events v. 5.0 (CTCAE).

    Time frame: Through study completation (up to 37 weeks)

  4. Incidence of injection site reactions

    Incidence of injection site reactions and general reactions associated with intraarticular administration

    Time frame: Through study completation (up to 37 weeks)

  5. Standard laboratory parameters

    Standard laboratory (haematology, biochemistry, liver and urine analysis) parameters.

    Time frame: Through study completion (up to 37 weeks)

Secondary outcomes

  1. CCI: Composite change index

    The CCI is a semiquantitative scoring system designed to assess target joint synovitis by integrating multiple clinical variables. It incorporates changes in joint pain measured by the Visual Analogue Scale (jVAS), clinical evaluation of joint swelling and tenderness, the patient's assessment of functional disability, and both patient and investigator global assessments of treatment efficacy. The resulting score ranges from 0 (no improvement) to 10 (maximal therapeutic effect).

    Time frame: Every 4 weeks, up to week 37

  2. SF-36

    Changes in Short Form Health Survey 36. The SF-36 is a validated, patient-reported measure of overall health status, comprising multi-item scales measuring each of the following 8 health concepts: (1) physical functioning, (2) role limitations due to physical health, (3) bodily pain, (4) social functioning, (5) emotional well-being, (6) role limitations due to emotional problems, (7) vitality (energy/fatigue), and (8) general health perceptions. Each healt concept is scored separately, with scores ranging from 0 (worst possible health status) to 100 (best possible health status).

    Time frame: Every 4 weeks, up to week 37

  3. Joint inflammation

    Changes in target joint inflammation (synovitis) assessed by gray-scale ultrasound (GSUS) and power doppler ultrasound (PDUS). Ultrasound assessment of the treated joint will be performed using gray-scale (to evaluate hypoechoic synovial hypertrophy) and power Doppler (to assess synovial vascularity). Semiquantitative scoring will be applied to each modality separately, as well as in a combined score, ranging from grade 0 (normal) to grade 3 (severe synovitis).

    Time frame: Every 4 weeks, up to week 37

  4. SDAI

    Changes in Simple Disease Activity Index. The SDAI is a validated tool for assessing rheumatoid arthritis disease activity. It sums the tender and swollen joint counts, patient and physician global assessments of disease activity, and C-reactive protein levels in serum. Scores indicate disease activity: ≤3.3 (remission), \>3.3-11 (low), \>11-26 (moderate), and \>26 (high).

    Time frame: Every 4 weeks, up to week 37

  5. Pharmacokinetic profile

    Pharmacokinetic profile of intra-articular F8IL10.

    Time frame: Every 2 weeks, up to week 7

  6. HAFA

    Formation of human anti-fusion protein antibodies (HAFA) against F8IL10.

    Time frame: Every 4 weeks, up to week 17

07

Study locations

1 of 2 sites recruiting
  • Arcispedale Santa Maria Nuova
    Reggio Emilia, Reggio Emilia 42123, Italy
    Not yet recruiting
    • Filippo Crescentini · Principal investigator
  • Azienda Ospedaliera Universitaria Integrata Verona c/o Policlinico GB Rossi (Borgo Roma), Dep. Reumatologia
    Verona, VR 37134, Italy
    Recruiting
    • Elena Fracassi · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Sep 2028, 30 months after the start.

Of 128 industry-sponsored phase 1 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's planned 30 months is above that.

Counting every sponsor, half of 148 studies reached it within 16 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2025
First posted
Nov 24, 2025
StartActual
Mar 4, 2026
Primary completionEst.
Sep 30, 2028
CompletionEst.
Sep 30, 2029
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
42→54
Oct 14, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionMAD, MTD and RD: how it is measured was reworded
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Enrollment 42→54
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionMAD, MTD and RD: how it is measured was reworded
    + 4 other changes: verification date, description, design details and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07245992
Lead sponsor
Philogen S.p.A.
Responsible party
Sponsor
First posted
Nov 24, 2025
Start date
Mar 4, 2026
Primary completion
Sep 30, 2028 (estimated)
Completion
Sep 30, 2029 (estimated)
Last update
Oct 14, 2026

Study contacts

Louis Plüss
Contact
louis.pluss@philogen.com
+41 43 544 88 04
Federica Bastioli, Pharmaceutical Chemist
Contact
regulatory@philogen.com

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion